Are Peptides Legal in Arizona? (2026)

The federal rules that apply in Arizona, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Arizona:

• Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
• Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Arizona. The PCAC vote page has every tally.
• GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Arizona law adds

Arizona's controlled-substances law (A.R.S. § 36-2501 et seq. (Uniform Controlled Substances Act); criminal drug definitions and offences at A.R.S. § 13-3401 et seq.) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (azleg.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Arizona's schedules or in a Arizona-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Arizona defines anabolic steroids as dangerous drugs by a closed list of 23 named steroids; human growth hormone, somatropin and hCG are not on it, so only the federal HGH statute applies. (A.R.S. § 13-3401(6)(e)) (azleg.gov)

Compounded semaglutide and tirzepatide

No Arizona Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Arizona pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No Arizona medical board guidance specific to peptide therapy was located. A Arizona prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Arizona

A.R.S. § 13-3406(A)(1) makes possessing a prescription-only drug without a valid prescription a class 1 misdemeanor, which reaches prescription products such as semaglutide; no Arizona provision specifically covers unscheduled research peptides such as BPC-157, so the federal rules apply there. (azleg.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Arizona is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. A.R.S. § 36-3606 requires telehealth prescribing to follow Arizona's standards of care and prescribing laws, with no in-person examination requirement and no audio-only ban; prescription monitoring registration applies only to controlled substances, which GLP-1s are not. A relationship is normally established by synchronous audio-video; an asynchronous questionnaire alone does not meet the standard. (azleg.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Arizona law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Enforcement in Arizona

The Bureau found no Arizona-level action against a peptide seller, clinic or compounded-GLP-1 seller between 2023 and September 2026. Federal actions apply regardless of state; the enforcement tracker lists them.

Editor's note. A 2026 Arizona bill on sourcing, testing and advertising of compounded GLP-1s was introduced but not enacted. No Arizona Board of Pharmacy GLP-1 guidance or attorney general peptide action was located with a primary source.

Frequently asked questions

Is BPC-157 legal in Arizona?

Arizona has not scheduled BPC-157, so possessing it is not a Arizona offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Arizona?

Yes. A.R.S. § 36-3606 requires telehealth prescribing to follow Arizona's standards of care and prescribing laws, with no in-person examination requirement and no audio-only ban; prescription monitoring registration applies only to controlled substances, which GLP-1s are not. A relationship is normally established by synchronous audio-video; an asynchronous questionnaire alone does not meet the standard. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in Arizona?

Only with a valid prescription for an approved use. Arizona does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

• https://www.azleg.gov/ars/13/03401.htm
• https://www.azleg.gov/ars/36/03606.htm
• https://www.azleg.gov/ars/13/03406.htm

Every Arizona fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.